← Back to Search

Biomarker Analysis for Gynecologic Cancers

N/A

Recruiting

Led By Amit Oza, M.D.

Research Sponsored by University Health Network, Toronto

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Patient must be ≥16 years of age at the time of consent.

Patients with probable diagnoses of gynecological malignancy (ovarian, tubal, primary peritoneal, uterine, cervical, vulvar and rare gynecological cancers) and confirmed to be undergoing upfront debulking surgery/radiation

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 5 years

Awards & highlights

Study Summary

This trial is studying gene changes or protein expression of tumors in women with gynecologic cancer.

Who is the study for?

This study is for individuals with probable gynecological cancers (like ovarian, uterine, cervical) who are set to undergo surgery or radiation. Participants must understand the study and agree in writing, have a life expectancy of at least 3 months, be willing to provide tissue and blood samples for research, be 16 years or older, and have an ECOG Performance Status of 2 or less.Check my eligibility

What is being tested?

The trial involves collecting tumor tissue during surgery and drawing blood from patients with gynecological cancers. Researchers aim to learn about gene changes or protein levels in tumors to improve understanding of cancer behavior and treatment responses.See study design

What are the potential side effects?

Since this trial does not involve testing new drugs but rather collects data through tissue collection and blood draws, typical side effects associated with drug interventions are not expected. However, there may be general risks related to surgical procedures and discomfort from blood draws.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I am 16 years old or older.

Select...

I have a gynecological cancer and am confirmed for initial major surgery or radiation.

Select...

I can take care of myself and perform daily activities.

Select...

I agree to give tissue and blood samples for the study.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 5 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~5 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 5 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Genomic and immune signatures in terms of overall survival

Genomic and immune signatures in terms of progression free survival

Trial Design

1Treatment groups

Experimental Treatment

Group I: Tumor tissue and blood samples collectionExperimental Treatment2 Interventions

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Blood draws

2010

Completed Phase 2

~520

0 / 4Eligibility criteria met

Find a Location

Who is running the clinical trial?

University Health Network, TorontoLead Sponsor

1,472 Previous Clinical Trials

484,504 Total Patients Enrolled

5 Trials studying Gynecologic Cancers

908 Patients Enrolled for Gynecologic Cancers

Amit Oza, M.D.Principal InvestigatorPrincess Margaret Cancer Centre

10 Previous Clinical Trials

831 Total Patients Enrolled

1 Trials studying Gynecologic Cancers

510 Patients Enrolled for Gynecologic Cancers

Media Library

Tumour tissue collection Clinical Trial Eligibility Overview. Trial Name: NCT03420118 — N/A

Gynecologic Cancers Research Study Groups: Tumor tissue and blood samples collection

Gynecologic Cancers Clinical Trial 2023: Tumour tissue collection Highlights & Side Effects. Trial Name: NCT03420118 — N/A

Tumour tissue collection 2023 Treatment Timeline for Medical Study. Trial Name: NCT03420118 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers are participating in this experiment?

"Affirmative. The details hosted on clinicaltrials.gov demonstrate that this medical research, which was initially shared on December 21st 2017, is actively seeking participants. Approximately 250 subjects must be recruited from one location for the experiment to continue."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of Biomarkers in Gynecological Cancers

2017. "Study of Biomarkers in Gynecological Cancers". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03420118.